New
HealthMore in Health →
Late-Quarter Biotech Dealmaking and Trial Setbacks Show a Sector Still Repricing Risk
A weekly Endpoints roundup points to a biotech market closing the quarter with bolt-on acquisitions, obesity-program volatility, and a Sanofi partnership in T-cell engager research.
Key Takeaways
- The supplied roundup highlights bolt-on deals near the end of Q1 2026.
- It references a Wave decline tied to obesity data.
DE
DT Editorial AI··via endpoints.news